bluuebunny/crossref_metadata_2025_split huggingface dataset:
Comparison of a polymer‐free rapamycin‐eluting stent (YUKON) with a polymer‐based paclitaxel‐eluting stent (TAXUS) in real‐world coronary artery lesions
Authors: Ruef Johannes , Störger Hans , Schwarz Franz , Haase, Jürgen 
Published: February 2008

AbstractBackground: In selected patient cohorts the polymer‐free rapamycin‐eluting YUKON stent (A) has demonstrated noninferiority compared with the polymer‐based paclitaxel‐eluting TAXUS stent (B). To test for equivalency in unselected real‐world patients with coronary lesions of various complexities, we retrospectively compared both stent designs. Methods: A total of 410 patients with symptomatic CAD were successfully treated with A (n = 205) or with B (n = 205). Baseline clinical characteristics, coronary lesion location, lesion length, and the number of stents implanted per lesion were equally distributed between the treatment groups. All patients underwent QCA‐analysis at baseline. Clinical follow‐up with assessment of MACE and noncardiac deaths was obtained at 30 days and 6 months. Results: Nominal stent diameter was 2.96 ± 0.38 mm in Group A vs. 3.05 ± 0.42 mm in Group B (P = 0.2); nominal length of stented segmentwas 22.97 ±13.0 mm vs. 23.63 ± 10.0 (P = 0.56). Analysis of MACE after 6 months resulted in one angiographically documented stent thrombosis causing MI in B (0.2%) vs. none in A. No other MI or cardiac deaths occurred in either group, while two noncardiac deaths in A (1.0%) were reported. Fifteen target lesion revascularizations (7.3%) were performed in A vs. 7 (3.4%) in B. Differences in study endpoints at 6 months did not reach statistical significance (P > 0.05). Conclusions: Up to 6 months after PCI of real‐world coronary lesions, there were no statistically significant differences in MACE between patients treated with the polymer‐free rapamycin‐eluting YUKON stent and the polymer‐based paclitaxel‐eluting TAXUS stent. © 2008 Wiley‐Liss, Inc.
Intracoronary infusion of autologous mononuclear bone marrow cells in patients with acute myocardial infarction treated with primary PCI: Pilot study of the multicenter HEBE trial
Authors: Hirsch Alexander , Nijveldt Robin , van der Vleuten Pieter A. , Tio René A. , van der Giessen Willem J. , Marques Koen M.J. , Doevendans Pieter A. , Waltenberger Johannes , ten Berg Jurrien M. , Aengevaeren Wim R.M. , Biemond Bart J. , Tijssen Jan G.P. , van Rossum Albert C. , Piek Jan J. , Zijlstra Felix 
Published: February 2008

AbstractObjective: This study was a pilot trial to determine safety and feasibility of intracoronary infusion of mononuclear bone marrow cells (MBMC) in patients with acute myocardial infarction (MI). Background: Studies reporting the effect of MBMC therapy on improvement of left ventricular (LV) function have shown variable results. The HEBE trial is a large multicenter, randomized trial that currently enrolls patients. Prior to this trial we performed a pilot study. Methods: Twenty‐six patients with a first acute MI were prospectively enrolled in eight centers. Bone marrow aspiration was performed at a median of 6 days after primary PCI (interquartile range, 5–7 days). MBMC were isolated by gradient centrifugation and were infused intracoronary the same day. All patients underwent magnetic resonance imaging before cell infusion and after 4 months. Clinical events were assessed up to 12 months. Results: Within 10 hr after bone marrow aspiration, 246 ± 133 × 106 MBMC were infused, of which 3.9 ± 2.3 × 106 cells were CD34+. In one patient, this procedure was complicated by local dissection. LV ejection fraction significantly increased from 45.0 ± 6.3% to 47.2 ± 6.5% (P = 0.03). Systolic wall thickening in dysfunctional segments at baseline improved with 0.9 ± 0.7 mm (P < 0.001). Infarct size decreased 37% from 17.8 ± 8.2 to 11.2 ± 4.2 gram (P < 0.001). During 12‐month follow‐up, 3 additional revascularizations were performed and an ICD was implanted in one patient, 3 weeks after PCI. Conclusion: In patients with acute MI, intracoronary infusion of MBMC is safe in a multicenter setting. At 4‐month follow‐up, a modest increase in global and regional LV function was observed, with a concomitant decrease in infarct size. © 2008 Wiley‐Liss, Inc.
Cardiac perforation and tamponade 3 months after transcatheter PFO closure by STARFlex device: A case report
Authors: Motreff Pascal , Dauphin Claire , Souteyrand Géraud 
Published: February 2008

AbstractPercutaneous Patent Foramen Ovale (PFO) closure after paradoxical embolism has become established as a safe, effective and validated procedure. The use of dedicated devices by experienced operators allows for low complication rates and good clinical results in the prevention of paradoxical embolism recurrence. This has led to a widespread use of the technique. However, late complications have been reported after the implantation of different types of devices. We report the first case of cardiac tamponade due to atrial wall erosion, which occurred three months after the implantation of a STARflex device (Nitinol Medical Technologies, Boston, Massachusetts, USA) in a 57 year‐old‐patient Transoesophageal echocardiographic images and surgical views of the perforation related to the device are presented. This report describes treatment of a late complication that arose following implantation of a STARflex device. © 2008 Wiley‐Liss, Inc.
Vulnerable plaque intervention: State of the art
Authors: Young John J. , Phillips Harry R. , Marso Steven P. , Granada Juan F. , McPherson John A. , Waksman Ron , Steinhubl Steven R. , Schwartz Robert S. , Stone Gregg W. 
Published: February 2008

AbstractProgressive atherosclerotic disease is responsible for many of the late adverse clinical events that detract from the high procedural and clinical success of percutaneous coronary intervention. Despite recent advances in catheter based technology for the treatment of obstructive coronary artery disease, the greater risk to the patient over time may in fact come from the significant rate of acute coronary events triggered by nonculprit and/or nonobstructive coronary artery lesions. These areas of vulnerability within the epicardial coronary tree have generated a great deal of interest surrounding the concepts of vulnerable plaque (VP), vulnerable blood and the vulnerable patient. This ‘state of the art’ review discusses the limitations of coronary angiography alone in providing risk assessment; reviews the underlying biological concepts of VP; discusses evolving noninvasive and invasive imaging technologies for the detection of VP; and finally provides a futuristic look at how the field of interventional cardiology may transcend the traditional angiogram and move toward a more comprehensive treatment approach that benefits the patients' overall coronary health. © 2008 Wiley‐Liss, Inc.
ASD and PFO closure with the Solysafe septal occluder—Results of a prospective multicenter pilot study
Authors: Ewert Peter , Söderberg Bjoern , Dähnert Ingo , Hess Otto , Schuler Gerhard , Bussmann Christiane , Bernhard Jerome , Sick Peter 
Published: February 2008

AbstractObjective:We report the results of a prospective multicenter pilot study performed in Germany, Sweden, and Switzerland with a new self‐centering device for transcatheter closure of an atrial septal defect (ASD) or a patent foramen ovale (PFO) called the Solysafe Septal Occluder.Interventions:The device was successfully implanted in 44 patients. In 15 patients with a median age of 40 years (range 6–76 years), a Solysafe device was successfully implanted in an ASD. The median size of the stretched defects was 17 mm (range 10–21 mm). Three 15‐mm devices, eight 20‐mm devices, and four 25‐mm devices were used. Procedure time ranged from 40 to 107 min (median 66 min) and fluoroscopic time from 5.3 to 17.5 min (median 12 min). In 29 patients with a median age of 47 years (range 15–78 years), a Solysafe device was implanted in a PFO. The procedure time ranged from 21 to 155 min (median 51 min) and fluoroscopic time from 3.1 to 31.3 min (median 7.6 min).Results:At discharge, 1 of the 29 patients (3%) had a small shunt. No patient in either the ASD or the PFO group had any major complication. Six months after implantation, the overall closure rate with the Solysafe septal occluder in both groups was 100% (44/44).Conclusion:With the self‐centering Solysafe Septal Occluder, PFOs, and ASDs with a stretched diameter of up to 21 mm can be effectively closed with very high occlusion rates. © 2008 Wiley‐Liss, Inc.
Percutaneous transcatheter closure of patent foramen ovale with the Amplatzer Cribriform septal occluder
Authors: Silvestry Frank E. , Naseer Nauman , Wiegers Susan E. , Hirshfeld John W. , Herrmann Howard C. 
Published: February 2008

AbstractObjectives:We tested the feasibility of percutaneous patent foramen ovale (PFO) closure utilizing the Amplatzer multifenestrated Cribriform atrial septal occluder device.Background:This device recently became available and may offer unique advantages for closure of PFO.Methods:Nineteen consecutive patients who underwent closure of PFO with the Cribriform device for a variety of indications under intracardiac echocardiographic and fluoroscopic guidance were studied. The degree of shunting was quantified pre‐ and postprocedure by echocardiography using both Doppler and agitated saline administration. The results with this device were compared to the prior 19 patients who underwent closure with a CardioSeal device.Results:The mean age of patients was 52 years and 47% were female. Indications for closure were paradoxical embolism in 17 patients, and hypoxemia due to right to left shunt in 2 patients. The postprocedure bubble contrast study showed a marked improvement in right to left shunting with 13 patients (68%) demonstrating no shunt flow, 4 (21%) having trace shunting, and 2 (11%) mild shunting. There were no device‐related complications. The mean procedure time was 28 ± 10 min. In comparison to the CardioSeal device, a trend was apparent in terms of a greater percentage of patients with immediate closure with the Cribriform device, although a similar percentage of defect closure was seen at 6 months with both devices. Procedure time was shorter with the Cribriform device, related in part to the reduced need for balloon sizing.Conclusions:This initial experience suggests a number of favorable characteristics of the Amplatzer Cribriform device for PFO closure. © 2007 Wiley‐Liss, Inc.
Percutaneous closure of nonrestrictive aortopulmonary window in three infants
Authors: Trehan Vijay , Nigam Arima , Tyagi Sanjay 
Published: February 2008

AbstractAortopulmonary (AP) window, a communication between ascending aorta and pulmonary artery, is usually nonrestrictive and causes severe pulmonary vascular obstructive disease early in life. Only in 10% of the cases it is restrictive. There are sporadic case reports [1–8] of device closure of AP window which are mostly confined to these restrictive AP windows, that too in adults or relatively older children. Till date there is a single case report of device closure of nonrestirctive AP window in an infant [8]. We report our single experience of device closure of large, nonrestrictive AP windows in 3 infants. Percutaneous closure of AP window in each of the three patients was done by a different type of device i.e. duct occluder, muscular VSD occluder and perimembranous VSD occluder. © 2008 Wiley‐Liss, Inc.
Drug‐eluting stenting of unprotected left main coronary artery stenosis in patients with orthotopic heart transplantation: Initial clinical experience
Authors: Lee Michael S. , Chun Kook‐Jin , Tobis Jonathan M. 
Published: February 2008

AbstractObjectives:To assess the safety and efficacy of percutaneous coronary intervention (PCI) with drug‐eluting stents (DES) in orthotopic heart transplantation (OHT) patients with unprotected left main coronary artery (ULMCA) disease.Background:Accelerated transplant coronary artery disease occurs in 50% of patients at 5 years and is the major cause of death following OHT. The optimal treatment for ULMCA disease in OHT patients is unknown.Methods:From April 2003 to December 2006, five OHT patients with ULMCA disease underwent PCI with DES at the University of California, Los Angeles, Medical Center.Results:Technical success was achieved in all five patients. At a median follow‐up of 518 days (range 124–990 days), all five patients were alive and free from death, myocardial infarction, and target vessel revascularization. No binary restenosis was present in four patients who underwent surveillance angiography. One patient underwent repeat OHT for progressive left ventricular dysfunction.Conclusions:In OHT patients, ULMCA PCI with DES is feasible with an excellent technical success rate and is a reasonably palliative treatment option for this difficult patient population. © 2008 Wiley‐Liss, Inc.
Hemodynamic rounds series: Left heart catheterization and mitral balloon valvuloplasty in a patient with a mechanical aortic valve
Authors: Kosmicki Douglas , Michaels Andrew D. 
Published: February 2008

AbstractPatients with rheumatic heart disease and a history of mechanical aortic valve replacement will occasionally present with significant mitral stenosis for consideration of mitral balloon valvuloplasty. The conventional retrograde trans‐aortic method for left heart catheterization cannot be done for patients with a mechanical aortic valve. We present a patient with a mechanical aortic valve who underwent successful left heart catheterization and mitral valvuloplasty via a transseptal approach. A 5 French pigtail catheter was advanced through the left atrial 8 French Mullins sheath into the left ventricle, for simultaneous pressure measurement across the mitral valve. This manuscript discusses the strengths and weaknesses of several approaches for left heart catheterization in patients with a mechanical aortic valve. © 2008 Wiley‐Liss, Inc.
Determinants of coronary arterial flow‐mediated dilatation following percutaneous coronary intervention
Authors: McGrady Michele , Thanyasiri Panuratn , Bailey Brian P. , Celermajer David S. , Adams Mark R. 
Published: February 2008

AbstractObjective: It has previously been observed that coronary diameter may increase following relief of flow‐limiting obstruction. Flow mediated dilatation (FMD) is a fundamental adaptive mechanism for arteries, which is dependent on intact endothelial function. We thus aimed to characterize whether the degree of this flow‐mediated dilatation was related to risk factors, which may impair endothelial function. Design: We measured coronary diameter with quantitative angiography before and after relief of chronic total or subtotal (≥99%) occlusion in 171 patients, in which TIMI‐0 or TIMI‐1 flow was rapidly restored to TIMI‐3 (with attendant increase in flow hypothesized to result in FMD). Patients: Of the 171 patients, 73% were male, 62% were current or ex‐smokers, 47% were diabetic, 53% had hypertension, 64% had dyslipidemia (documented hypercholesterolemia or total cholesterol >5.0 mg/dL) and 65% were taking statin therapy. Results: Mean vessel diameter was 2.8 ± 0.7 mm and flow‐mediated dilatation measured 15.1% ± 20.1% in target vessel, compared with 1.6 ± 3.1 in control vessels (P < 0.05). FMD was strongly and inversely related to baseline vessel diameter (r = −0.48, P < 0.001). The degree of vessel dilation correlated negatively with the presence of diabetes (r = −0.33, P < 0.001), smoking (r = −0.30, P < 0.001) and extent of coronary artery disease (CAD, r = −0.17, P = 0.01) and positively with the use of statins (r = 0.27, P = 0.001). These factors, apart from extent of CAD, remained significant predictors of FMD on multivariate analysis. Conclusions: FMD occurs in human coronary arteries following restoration of flow. The magnitude of FMD appears related to vascular risk factors and their treatment. © 2008 Wiley‐Liss, Inc.
Successful use of the Heartrail III catheter as a stent delivery catheter following failure of conventional techniques
Authors: Mamas M.A. , Fath‐Ordoubadi F. , Fraser D. 
Published: February 2008

AbstractThe Terumo “five in six” system involves insertion of an extra length, 5 Fr Terumo guide catheter (Heartrail, Terumo) into a standard 6 Fr guide catheter so that the tip protrudes beyond the 6 Fr guide. This system increases backup support and has been used successfully to advance balloon catheters across chronic total occlusions. We describe the use of this system to facilitate extra deep intubation, enabling distal stent delivery beyond proximal points of obstruction that had been unsuccessful using more conventional techniques. © 2008 Wiley‐Liss, Inc.
Bidirectional manipulation facilitating percutaneous retrieval of Swan‐Ganz catheter entrapped in tricuspid valve apparatus
Authors: Khard Aleem , Lefèvre Thierry 
Published: February 2008

AbstractWe present a case of a 69‐year‐old male patient who, after uneventful coronary artery bypass grafting, had a Swan‐Ganz catheter entrapped in the tricuspid apparatus. An original technique to remove the catheter percutaneously was used after unsuccessful attempts using a conventional lasso technique. © 2008 Wiley‐Liss, Inc.
Carboxylate Ligands Drastically Enhance the Rates of Oxo Exchange and Hydrogen Peroxide Disproportionation by Oxo Manganese Compounds of Potential Biological Significance
Authors: Dubois Lionel , Pécaut Jacques , Charlot Marie‐France , Baffert Carole , Collomb Marie‐Noëlle , Deronzier Alain , Latour Jean‐Marc 
Published: February 2008

AbstractTo mimic the carboxylate‐rich active site of the manganese catalases more closely we introduced carboxylate groups into dimanganese complexes in place of nitrogen ligands. The series of dimanganese(III,IV) complexes of tripodal ligands [Mn2(L)2(O)2]3+/+/−/3− was extended from those of tpa (1) and H(bpg) (2) to those of H2(pda) (3) and H3(nta) (4) (tpa=tris‐picolylamine, H(bpg)=bis‐picolylglycylamine, H2(pda)=picolyldiglycylamine, H3(nta)=nitrilotriacetic acid). While 3 [Mn2(pda)2(O)2][Na(H2O)3] could be synthesized at −20 °C and characterized in the solid state, 4 [Mn2(nta)2(O)2]3− could be obtained and studied only in solution at −60 °C. A new synthetic procedure for the dimanganese(III,III) complexes was devised, using stoichiometric reduction of the dimanganese(III,IV) precursor by the benzil radical with EPR monitoring. This enabled the preparation of the parent dimanganese(III,III) complex 5 [Mn2(tpa)2(O)2](ClO4)2, which was structurally characterized. The UV/visible, IR, EPR, magnetic, and electrochemical properties of complexes 1–3 and 5 were analyzed to assess the electronic changes brought about by the carboxylate replacement of pyridine ligands. The kinetics of the oxo ligand exchanges with labeled water was examined in acetonitrile solution. A dramatic effect of the number of carboxylates was evidenced. Interestingly, the influence of the second carboxylate substitution differs from that of the first one probably because this substitution occurs on an out‐of‐plane coordination while the former occurs in the plane of the [Mn2O2] core. Indeed, on going from 1 to 3 the exchange rate was increased by a factor of 50. Addition of triethylamine caused a rate increase for 1, but not for 3. The abilities of 1–3 to disproportionate H2O2 were assessed volumetrically. The disproportionation exhibited a sensitivity corresponding to the carboxylate substitution. These observations strongly suggest that the carboxylate ligands in 2 and 3 act as internal bases.
Single‐Crystal X‐ray Study of Ba2Cu2Te4O11Br2 and Its Incommensurately Modulated Superstructure Companion
Authors: Fredrickson Takagi Rie , Johnsson Mats , Lidin Sven 
Published: February 2008

AbstractCompounds containing lone‐pair elements such as TeIV are very interesting from the structural point of view, as the lone‐pair nonbonding regions create low‐dimensional geometrical arrangements. We have synthesized two new compounds with these features—Ba2Cu2Te4O11Br2 (I) and Ba2Cu2Te4O11−δ(OH)2δBr2 (II, δ≈0.57)—as members of the AE‐M‐Te‐O‐X (AE=alkaline‐earth metal, M=transition metal, X=halide) family of compounds by solid‐state reactions. Preliminary single‐crystal X‐ray analysis indicated that compound I crystallizes in the orthorhombic system, but attempts at refinement proved unsatisfactory. Closer inspection of the reciprocal lattice revealed systematic, non‐crystallographic absences that indicate twinning. The structure is in fact triclinic, space group C$\bar 1$ (equivalent to P$\bar 1$), with unit cell parameters (at 120 K) of a=10.9027(9), b=15.0864(7), c=9.379(2) Å, β=106.8947°. It is layered and built from [TeO3E] tetrahedra, [TeO3+1E] trigonal bipyramids (where E is the lone pair of TeIV), [CuO4] squares and irregular [BaO10Br] polyhedra. The crystal structure of II shows the same basic structure as I but contains additional oxygen, probably in the form of OH groups. The presence of satellites reveals that ordering on this O site creates an incommensurate modulation, primarily affecting Br and Te. The modulated structure of II was solved in the triclinic superspace group X$\bar 1$(αβγ)0 with the vector q≈1/16 c*.
Vesicles to Concentrate Iron in Low‐Iron Media: An Attempt to Mimic Marine Siderophores
Authors: Bednarova Lucie , Brandel Jérémy , d'Hardemare Amaury du Moulinet , Bednar Jan , Serratrice Guy , Pierre Jean‐Louis 
Published: February 2008

AbstractAmphiphilic catechol‐type iron chelators were studied with the aim of mimicking the properties of marine bacterial siderophores. The FeIII complexation constants and aqueous solution speciation of LS10, a sulfonated catechol unit that has a C10 lipophilic carbon chain connected by an amide linkage, were determined by spectrophotometric titration. The calculated value of pFe3+ is 18.1 at pH 7.4. Cryogenic transmission electron microscopy showed that the tris(catecholate) ferric complex formed at physiological pH initially assembles into micelles, in which the catecholate–iron units stay on the exterior of the micelle. The average diameter of these micelles was estimated to be 4.2 nm. The micelles then slowly rearrange into clusters of different sizes, which leads to the formation of unilamellar and bilamellar vesicles. The reorganization processes are comparable to those observed by Butler et al. for the marinobactin siderophores produced by marine bacteria, but in contrast to the marinobactins, vesicles of the Fe3+–LS10 complex form without an excess of iron relative to ligand concentration. The time‐dependent micelle‐to‐vesicle transition is discussed herein.
TEMPO/HCl/NaNO2 Catalyst: A Transition‐Metal‐Free Approach to Efficient Aerobic Oxidation of Alcohols to Aldehydes and Ketones Under Mild Conditions
Authors: Wang Xinliang , Liu Renhua , Jin Yu , Liang Xinmiao 
Published: February 2008

AbstractHydrochloric acid, a very inexpensive and readily available inorganic acid, has been found to cooperate exquisitely with NaNO2/TEMPO in catalyzing the molecular‐oxygen‐driven oxidation of a broad range of alcohol substrates to the corresponding aldehydes and ketones. This transition‐metal‐free catalytic oxidative conversion is novel and represents an interesting alternative route to the corresponding carbonyl compounds to the metal‐catalyzed aerobic oxidation of alcohols. The reaction is highly selective with respect to the desired product when carried out at room temperature in air at atmospheric pressure. Notably, the use of very inexpensive NaNO2 and HCl in combination with TEMPO for this highly selective aerobic oxidation of alcohols in air at ambient temperature makes the reaction operationally and economically very attractive. The results of mechanistic studies, performed with the aid of electrospray ionization mass spectrometry (ESI‐MS), are presented and discussed. TEMPO, TEMPOH, and TEMPO+ were observed in the redox cycle by means of ESI‐MS. On the basis of these observations, a mechanism is proposed that may provide an insight into the newly developed aerobic alcohol oxidation.